RIGEL PHARMACEUTICALS, INC. (RIGL) Operating Margin
- Operating margin · 12 months: Value 31.45%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 31.45% | Operating income / revenue. Period ending 2026-06-30. $87.05M ÷ $276.79M × 100 ≈ 31.45% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 87.05M USD | Operating Income (Loss) |
| Revenue | 276.79M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 23.84M USD | Cost of Goods and Services Sold |
| Research and development | 43.67M USD | Research and Development Expense |
| Selling, general and administration | 122.22M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $87.05M | $276.79M | $23.84M | $43.67M | $122.22M | 31.45% |
| 2026-03-31 | $124.58M | $299.77M | $19.82M | $36.53M | $118.84M | 41.56% |
| 2025-12-31 | $125.47M | $294.28M | $19.62M | $33.30M | $115.90M | 42.63% |
| 2025-09-30 | $118.95M | $282.08M | $19.45M | (m) | $115.43M | 42.17% |
| 2025-06-30 | $104.59M | $267.92M | $22.73M | (m) | $113.53M | 39.04% |
| 2025-03-31 | $43.93M | $203.08M | $21.03M | (m) | $112.33M | 21.63% |
| 2024-12-31 | $24.19M | $179.28M | $18.65M | (m) | $113.06M | 13.49% |
| 2024-09-30 | $9.50M | $157.47M | $16.65M | (m) | $110.39M | 6.03% |
| 2024-06-30 | $-9.02M | $130.30M | $9.89M | (m) | $108.20M | -6.92% |
| 2024-03-31 | $-14.73M | $120.35M | $8.16M | (m) | $106.46M | -12.24% |
| 2023-12-31 | $-20.49M | $116.88M | $7.11M | (m) | $105.74M | -17.53% |
| 2023-09-30 | $-20.38M | $132.37M | $3.66M | (m) | $111.06M | -15.39% |
| 2023-06-30 | $-34.32M | $126.64M | $2.64M | (m) | $112.10M | -27.10% |
| 2023-03-31 | $-42.01M | $129.58M | $2.60M | (m) | $112.78M | -32.42% |
| 2022-12-31 | $-55.55M | $120.24M | $1.75M | (m) | $112.45M | -46.20% |
| 2022-09-30 | $-79.05M | $89.37M | $1.89M | (m) | $104.79M | -88.45% |
| 2022-06-30 | $-80.43M | $88.51M | $1.79M | (m) | $101.77M | -90.87% |
| 2022-03-31 | $-80.51M | $84.95M | $888.00K | (m) | $97.17M | -94.77% |
| 2021-12-31 | $-12.50M | $149.24M | $1.08M | (m) | $91.89M | -8.37% |
| 2021-09-30 | $-9.90M | $147.28M | $917.00K | (m) | $89.19M | -6.73% |
| 2021-06-30 | $-3.90M | $144.12M | $906.00K | (m) | $83.75M | -2.71% |
| 2021-03-31 | $-8.24M | $133.88M | $1.06M | (m) | $80.29M | -6.16% |
| 2020-12-31 | $-28.97M | $108.62M | $895.00K | (m) | $76.60M | -26.67% |
| 2020-09-30 | $-27.48M | $105.57M | $752.00K | (m) | $73.09M | -26.03% |
| 2020-06-30 | $-25.74M | $108.04M | $922.00K | (m) | $73.78M | -23.82% |
| 2020-03-31 | $-29.69M | $102.42M | $954.00K | (m) | $73.07M | -28.98% |
| 2019-12-31 | $-69.09M | $59.29M | $906.00K | (m) | $74.59M | -116.53% |
| 2019-09-30 | $-49.22M | $81.75M | $916.00K | (m) | $77.65M | -60.21% |
| 2019-06-30 | $-61.55M | $65.75M | $675.00K | (m) | $77.59M | -93.62% |
| 2019-03-31 | $-66.33M | $57.13M | $394.00K | (m) | $76.46M | -116.09% |
| 2018-12-31 | $-72.68M | $44.51M | $287.00K | (m) | $70.00M | -163.30% |
| 2018-09-30 | $-101.43M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-94.92M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-88.15M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-79.62M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-69.19M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $-74.07M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $-68.38M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-69.74M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $-66.70M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $-50.74M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $-51.07M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-51.74M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $-61.36M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-75.62M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-87.11M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-91.25M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $-85.83M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $-88.72M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-86.14M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-89.47M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $-98.14M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $-99.78M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-101.78M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-99.38M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $-99.67M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $-92.14M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $-88.82M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-86.37M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $35.32M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-112.04M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |